Physician profile
Maher Dahdel
NPI 1104001031
$8,248.32
in general payments reported to CMS, 2019-2025
34 companies · $1,545 in 2025
The $1,545 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,223 · 2020: $765 · 2021: $865 · 2022: $438 · 2023: $993 · 2024: $1,419 · 2025: $1,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,744 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,744.46 |
| Education | $212.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $1,754.09 | 2019-2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Glaxosmithkline, LLC. | $988.72 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Electromed, INC. | $685.74 | 2023-2025 | Smartvest |
| Insmed, INC. | $601.26 | 2019-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $518.24 | 2019-2025 | Uptravi, Opsumit |
| Inspire Medical Systems, INC. | $484.97 | 2023-2025 | Inspire |
| Intuitive Surgical, INC. | $329.01 | 2022-2024 | Da Vinci Surgical System |
| Genzyme Corporation | $283.08 | 2021-2025 | |
| Veran Medical Technologies, INC. | $280.13 | 2020 | |
| Sunovion Pharmaceuticals INC. | $240.96 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.53 | 2019-2023 | Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $229.70 | 2019-2025 | Tezspire, Breztri |
| Abbvie INC. | $200.25 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $184.58 | 2021-2025 | Dupixent |
| United Therapeutics Corporation | $143.88 | 2019-2025 | Tyvaso |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $132.10 | 2021-2025 | Flexitouch Plus, Nimbl |
| Janssen Pharmaceuticals, INC | $116.22 | 2019 | |
| Merck Sharp & Dohme LLC | $109.90 | 2022-2025 | Winrevair |
| Mylan Specialty L.P. | $106.90 | 2019-2024 | Yupelri |
| Philips North America LLC | $96.64 | 2019-2024 | (Ak6) Vest Therapy |
| Novartis Pharmaceuticals Corporation | $89.87 | 2021-2025 | |
| Amgen INC. | $74.99 | 2022-2025 | Tavneos, Tezspire |
| Teva Pharmaceuticals USA, INC. | $56.74 | 2020-2021 | |
| Axsome Therapeutics, INC. | $51.82 | 2024 | Sunosi |
| Inari Medical, INC. | $50.38 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Harmony Biosciences LLC | $43.26 | 2022-2023 | Wakix |
| Grifols USA, LLC | $42.11 | 2019-2020 | |
| Shionogi INC | $22.94 | 2021 | |
| Olympus America INC. | $20.83 | 2021 | |
| Gilead Sciences, INC. | $19.21 | 2019 | |
| Allergan, INC. | $17.24 | 2020 | |
| Pfizer INC. | $16.73 | 2021 | |
| Phadia US INC. | $13.06 | 2020 | |
| Circassia INC. | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maher Dahdel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.